Literature DB >> 31128145

Palliative Radiation Therapy for Head and Neck Cancers.

Amardeep S Grewal1, Joshua Jones1, Alexander Lin2.   

Abstract

Patients with advanced head and neck cancers who are not eligible for curative treatment represent a challenging cohort of patients to manage given the complexity and severity of their presenting symptoms. Palliative radiation therapy, along with other systemic and surgical measures, has the potential to significantly improve the quality of life of such patients. There is little high-level evidence and a lack of consensus to direct the selection of an optimal palliative radiation regimen. An ideal palliative radiation regimen should alleviate symptoms secondary to the cancer with minimal treatment toxicity and side effects while improving a patient's quality of life. This review presents the treatment approaches, outcomes, and toxicities associated with different radiation regimens and proposes a multidisciplinary framework for the selection of an individualized treatment regimen for patients that centers around patient prognosis, goals of care, logistics of treatment, and the availability of other surgical and systemic therapies.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 31128145     DOI: 10.1016/j.ijrobp.2019.05.024

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

1.  [Randomized controlled trial for palliative radiotherapy of head and neck cancer-challenges remain].

Authors:  Alexander Fabian; David Krug; Jürgen Dunst
Journal:  Strahlenther Onkol       Date:  2020-11       Impact factor: 3.621

2.  Synergies Radiotherapy-Immunotherapy in Head and Neck Cancers. A New Concept for Radiotherapy Target Volumes-"Immunological Dose Painting".

Authors:  Camil Ciprian Mireştean; Anda Crişan; Călin Buzea; Roxana Irina Iancu; DragoşPetru Teodor Iancu
Journal:  Medicina (Kaunas)       Date:  2020-12-23       Impact factor: 2.430

3.  Hypofractionated Radiotherapy in Head and Neck Cancer Elderly Patients: A Feasibility and Safety Systematic Review for the Clinician.

Authors:  Antonio Piras; Luca Boldrini; Sebastiano Menna; Valeria Venuti; Gianfranco Pernice; Ciro Franzese; Tommaso Angileri; Antonino Daidone
Journal:  Front Oncol       Date:  2021-11-12       Impact factor: 6.244

4.  Long-Term Survival Following Palliative Chemoradiotherapy in an Elderly Patient With Advanced Squamous Cell Carcinoma in the Right Mandibular Gingiva.

Authors:  Yojiro Ishikawa; Rei Umezawa; Takaya Yamamoto; Kengo Ito; Keiichi Jingu
Journal:  Cureus       Date:  2022-02-11

5.  IGF-I and Hyaluronic Acid Mitigate the Negative Effect of Irradiation on Human Skin Keratinocytes.

Authors:  Celena A Sörgel; Rafael Schmid; Nina Stadelmann; Volker Weisbach; Luitpold Distel; Raymund E Horch; Annika Kengelbach-Weigand
Journal:  Cancers (Basel)       Date:  2022-01-24       Impact factor: 6.639

Review 6.  Recent developments in mesoporous polydopamine-derived nanoplatforms for cancer theranostics.

Authors:  Menglu Zhu; Yi Shi; Yifan Shan; Junyan Guo; Xuelong Song; Yuhua Wu; Miaolian Wu; Yan Lu; Wei Chen; Xiaoling Xu; Longguang Tang
Journal:  J Nanobiotechnology       Date:  2021-11-24       Impact factor: 10.435

7.  What Did the Pandemic Teach Us About Palliative Radiation in Head and Neck Cancer?

Authors:  Sushmita Ghoshal; Aditya Kumar Singla; Nagarjun Ballari; Ankita Gupta
Journal:  J Palliat Care       Date:  2021-12-06       Impact factor: 1.980

8.  Beam-Specific Spot Guidance and Optimization for PBS Proton Treatment of Bilateral Head and Neck Cancers.

Authors:  Karla Leach; Shikui Tang; Jared Sturgeon; Andrew K Lee; Ryan Grover; Parag Sanghvi; James Urbanic; Chang Chang
Journal:  Int J Part Ther       Date:  2021-06-25

9.  Patient-Reported Outcomes Assessing the Impact of Palliative Radiotherapy on Quality of Life and Symptom Burden in Head and Neck Cancer Patients: A Systematic Review.

Authors:  Alexander Fabian; Justus Domschikowski; Markus Hoffmann; Oliver Weiner; Claudia Schmalz; Jürgen Dunst; David Krug
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.